To test whether increasing the number of tumor-infiltrating DCs could further enhance the antitumor effect of SUP3 and PD-L1 blockade combination therapy, we used a B16F10-Flt3L tumor model, in which the B16F10 tumor cells could produce the hematopoietic growth factor Flt3L. This evidence concerns the gene CD274 and neoplasm.